

CONFIRMING PEAK IDENTIFICATION IN BIOANALYTICAL STUDIES UTILIZING XEVO TQ MS PRODUCT ION CONFIRMATION

Paul D. Rainville, Joanne Mather, and Robert S. Plumb Waters Corporation, Milford, MA, U.S.

INTRODUCTION

The accurate quantification of candidate pharmaceuticals in bioanalysis relies on the use of sensitive, specific methodology. The advent of atmospheric pressure ionization sources, in the late 1980s, allowed the simple interfacing of liquid chromatography with tandem quadrupole mass spectrometry. The selectivity and sensitivity provided by LC/MS/MS has made it the technique of choice for bioanalytical studies.

Bioanalytical scientists have relied on the specificity and sensitivity of the multiple reaction monitoring (MRM) MS acquisition mode to ensure that the correct analyte is quantified. However, even with the specificity of MRM analysis and modern sample preparation techniques, such as solid phase extraction, extraneous peaks can interfere during sample analysis. The appearance of an extra peak during MRM analysis could be due to chromatographic peak splitting, associated drug metabolites, or matrix interferences.

The occurrence of extra peaks during analysis would require additional experiments to correctly identify the analyte of interest. With a conventional tandem quadrupole mass spectrometer, this would require separate analysis to acquire full scan MS or full scan MS/MS spectra to confirm the identity of the peaks in question. With the introduction of the Waters® Xevo™ TQ MS, both MRM and full scan MS or product scan MS/MS can now be acquired during a single injection.



Figure 1. The ACQUITY UPLC System with the Xevo TQ MS.

EXPERIMENTAL

Rat plasma was spiked with fluticasone propionate, a corticosteroid used for the treatment of asthma. The sample was then prepared by solid phase extraction utilizing an Oasis® HLB µElution plate. The sample was analyzed using UltraPerformance LC® (UPLC®) coupled with tandem mass spectrometry.

LC conditions

LC system:	Waters ACQUITY UPLC [®] System
Column:	ACQUITY UPLC BEH C ₁₈ Columr
	2.1 x 50 mm, 1.7 μm
Column temp.:	45 °C
Flow rate:	500 µL/min
Mobile phase A:	0.1% NH ₄ OH
Mobile phase B:	Methanol
Gradient:	15 to 95 %B/1 min

MS conditions

MS system:	Waters Xevo TQ MS
lonization mode:	ESI positive
Capillary voltage:	3000 V
Cone voltage:	30 V
Desolvation temp.:	600 °C
Source temp.:	150 °C
Desolvation flow:	1000 L/Hr
Collision energy:	17 V
MRM transition:	m/z 501 > 293

[APPLICATION NOTE]

Product Ion Confirmation (PIC)

The novel collision cell design of the Xevo TQ MS allows for simultaneous acquisition of MRM and full scan MS data. Product Ion Confirmation (PIC) takes advantage of this capability to collect a high-quality full scan MS or MS/MS spectrum during MRM acquisition.¹ This MS or MS/MS spectrum is acquired after the apex of the MRM peak and before the return to baseline, Figure 2.



Figure 2. Schematic illustrating PIC data acquisition.

Furthermore, the fast data capture rate of the Xevo TQ MS allows for multiple full scan MS or MS/MS spectra to be acquired across the narrow, 2- to 3-second-wide chromatographic peaks that are typically generated during analysis when coupled with UPLC.

RESULTS

During the development of an LC/MS/MS method for fluticasone propionate, two peaks with the same MRM transitions were detected, Figure 3.



Figure 3. Analysis of rat plasma spiked with 100 ng/mL fluticasone propionate.

The product ion scan spectra simultaneously generated by the PIC function during analysis is displayed in Figure 3. Spectra (A) is that obtained from the peak eluting with a retention time of 0.69 minutes. Spectra (B) is that obtained from the peak eluting with a retention time of 0.85 minutes.

Each of the product ion scan spectra generated from the analysis were then compared to the product ion scan spectra obtained during sample tuning of the fluticasone propionate standard, Figure 4.

Here we can see that comparison of the two spectra show good agreement, confirming that the peak with the retention time of 0.85 minutes is the analyte of interest, fluticasone propionate. Thus, in one analytical run, we were able to identify the peak at 0.85 minutes as the analyte of interest without the need for further analysis.





Reference

1. Twohig M, Fujimoto G, Mather J, Plumb RS. Simultaneous Confirmation and Quantification using Xevo TQ MS: Product Ion Confirmation (PIC). Waters Application Note. 2008; 720002829en.



Figure 4. (A) Product scan comparison of fluticasone propionate standard and (B) Product scan acquired by PIC of analyte peak eluting at 0.85 min.



Waters, ACQUITY UPLC, UltraPerformance LC, and UPLC are registered trademarks of Waters Corporation. Xevo and The Science of What's Possible are trademarks of Waters Corporation. All other trademarks are the property of their respective owners.

©2009 Waters Corporation. Produced in the U.S.A. January 2009. 720002858en AG-UM Waters Corporation 34 Maple Street Milford, MA 01757 U.S.A. T: 1 508 478 2000 F: 1 508 872 1990 www.waters.com

